

PA Health & Wellness Pharmacy and Therapeutics Committee Meeting Minutes
1700 Bent Creek Blvd, Suite 200, Mechanicsburg, PA 17050

Wednesday, April 8, 2026 – 12:00 PM – 1:30 PM

Present: Jason Skaria, PharmD, Jill Schaeffer, RN, Michelle Bennett, RPh, Dr. Craig Butler, Dr. Chris Squillaro, Dr. John Shand, Grace Robinson (CHC Participant)

Absent: Dr. Kolin Good (voted), Dr. Venkateswara Davuluri (voted)

Non-Voting Members: Amy Nowacki (Pharmacy), Rhonda Montesano (Pharmacy), Shalyn Kline (Pharmacy), Spencer Knauss (Pharmacy), Tanayja Sams (Pharmacy), George Kimbrow (Clinical Policy Coordinator), Heather Clarke (Director of Case Management).

Call to Order: The PA Health & Wellness Pharmacy and Therapeutics Committee meeting called to order at 12:02 PM.

Adjourned: The PA Health & Wellness Pharmacy and Therapeutics Committee meeting was adjourned at 12:20 PM.

Next Meeting: Wednesday, July 15, 2026 – 12:00 PM

Submitted By: Shalyn Kline (PHW Pharmacy)

Committee Chair: Shalyn Kline

Date: 07/15/2026

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

Agenda Item	Discussion/Recommendation	Action	Next Steps	Owner
I. Introduction & Call to Order	Jason called the PA Health & Wellness Pharmacy & Therapeutics Committee meeting to order at 12:02 PM.	Meeting Called to Order		Jason Skaria
A. Introductions	Jason introduced Spencer Knauss, a new pharmacist on the PHW pharmacy team.	No action required or taken.		Jason Skaria
B. Announcements	Jason reminded all that 75% attendance is required for all voting members to remain as active committee members.	No action required or taken.		Jason Skaria
C. Explanation of the Review and Approval Process	I. Voting and vote totals II. Tie breaker III. Pennsylvania's Review and Approval Process	No action required or taken.		Jason Skaria
II. Approval of Meeting Minutes	A vote was taken for the approval of the minutes from Q1_2026. No objections were made. Motion to approve: Dr. John Shand Second motion to approve: Jill Schaeffer, RN	Adoption of Q1_2026 Meeting Minutes recorded as approved		Shalyn Kline
III. Old Business	No old business	No action required or taken.		Shalyn Kline
A. Policy Submission Status	There are 31 outstanding clinical policies awaiting approval.	No action required or taken.		Shalyn Kline
IV. New Business				
A. Provider Education	A vote was taken for the approval of the GLP-1 Receptor Agonist and DPP-4 Inhibitors Concurrent Use provider education. No objections were made.	The provider education was		Shalyn Kline

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

	Motion to approve: Michelle Bennett, RPh Second motion to approve: Jill Schaeffer, RN	Committee approved.		
B. FDA Updates	This is informational only and addresses recalls, new drugs, etc. No vote necessary.	Informational		Shalyn Kline
C. Guidelines – Drug Coverage Criteria	Review on Combined Summary Table for summary of revisions. A vote was taken for the approval of 4 new policies created, 33 policies had clinically significant change, 48 policies with no significant changes and 3 policies being retired for Medicaid. No objections, concerns or comments were made. Motion to approve: Dr. John Shand Second motion to approve: Jill Schaeffer, RN A vote was taken for the approval of 3 new policies created, 104 policies had clinically significant change, 120 policies with no significant changes and 2 policies being retired for CHIP. No objections, concerns or comments were made. Motion to approve: Dr. Chris Squillaro Second motion to approve: Dr. John Shand	The policy revisions were Committee approved.		Shalyn Kline
D. Additional Drug Lists and Policies and Procedures	A vote was taken for the approval of the Specialty Drug List. Motion to approve: Dr. Chris Squillaro Second motion to approve: Dr. John Shand A vote was taken for the approval of the 2 Pharmacy Policy & Procedures. Motion to approve: Dr. Chris Squillaro Second motion to approve: Dr. John Shand	The policy and drug lists revisions were Committee approved.		Shalyn Kline

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

	A vote was taken for the approval of the Maintenance (Extended Day Supply) Drug List. Motion to approve: Dr. Chris Squillaro Second motion to approve: Jill Schaeffer, RN			
E. Statewide PDL Updates	Shalyn reviewed as of 3/30/2026 Skilos (100mg and 1000mg) were changed to preferred without PA for members under 18 years to allow for more accurate dosing. The Sickle Cell Anemia Agents policy was updated to reflect this change. Shalyn reviewed as of 3/2/2026 the GLP-1 Receptor Agonist policy was updated to indicate injectable formulations over oral formulations.	No action required or taken.		Shalyn Kline
F. Highlights of New Medications/ Significant Changes	Nereus (tradipitant) is indicated for prevention of vomiting induced by motion. The cost is unknown at this time but is projected to be significant higher than alternatives, transdermal scopolamine, meclizine, diphenhydramine and promethazine. For the 170mg dose there was a 50-70% risk reduction in the incidence of vomiting compared to placebo. Dr. Shand and Shalyn discussed the place in therapy may be for members with concurrent anticholinergic medications and a great benefit of Nereus is likely the reduction in drowsiness.	No action required or taken.		Shalyn Kline
G. Complaints and Grievances Review	Shalyn stated that there was 1 determinations upheld and 3 overturned and 0 withdrawn during pre-grievance. 1 of the 4 determinations was for GLP-1 receptor agonists.	No action required or taken.		Shalyn Kline
H. Drug Utilization Review	Shalyn presented the drug utilization review, noted the numbers are for January and February, there were 5,405 DUR provider outreaches and only 325 were resolved. Fraud, Waste and Abuse – There were 90 Participants reviewed with 90 Morphine Milligram Equivalent (MME) or more. 35 participants were identified for provider outreach. Zero participants were identified with three or more practices/hospitals prescribing opioids.	No action required or taken.		Shalyn Kline

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

I. PBM Oversight	Prior Authorization Audits: - January – 97.03% pass rate - February – 96.12% pass rate - March – 99.43% pass rate Jason discussed we are working with the prior authorization team to increase the specificity of the denial language. Call Center: service levels were met for January and February. March data will be coming out next week.	No action required or taken.		Jason Skaria
K. Open Forum	The committee was asked if there is any topic they would like discussed in the next P&T meeting or if there were any questions. The committee did not have any questions or comments.	No action required or taken.		Shalyn Kline
Adjournment	The meeting was adjourned at 12:20 pm Jason asked for a motion to adjourn. Motion to approve: Dr. John Shand Second motion to approve: Jill Schaeffer, RN	Meeting adjourned		Jason Skaria

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).